ATE411311T1 - Tetrahydropyranverbindungen als tachykininantagonisten - Google Patents
Tetrahydropyranverbindungen als tachykininantagonistenInfo
- Publication number
- ATE411311T1 ATE411311T1 AT04717163T AT04717163T ATE411311T1 AT E411311 T1 ATE411311 T1 AT E411311T1 AT 04717163 T AT04717163 T AT 04717163T AT 04717163 T AT04717163 T AT 04717163T AT E411311 T1 ATE411311 T1 AT E411311T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- compounds
- tachykinin antagonists
- tetrahydropyran compounds
- tetrahydropyran
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0305281A GB0305281D0 (en) | 2003-03-07 | 2003-03-07 | Therapeutic agents |
GB0305282A GB0305282D0 (en) | 2003-03-07 | 2003-03-07 | Therapeutic agents |
GB0305279A GB0305279D0 (en) | 2003-03-07 | 2003-03-07 | Therapeutic agents |
GB0305280A GB0305280D0 (en) | 2003-03-07 | 2003-03-07 | Therapeutic agents |
GB0305283A GB0305283D0 (en) | 2003-03-07 | 2003-03-07 | Therapeutic agents |
GB0305823A GB0305823D0 (en) | 2003-03-13 | 2003-03-13 | Therapeutic agents |
GB0305822A GB0305822D0 (en) | 2003-03-13 | 2003-03-13 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE411311T1 true ATE411311T1 (de) | 2008-10-15 |
Family
ID=32966887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04717163T ATE411311T1 (de) | 2003-03-07 | 2004-03-04 | Tetrahydropyranverbindungen als tachykininantagonisten |
Country Status (8)
Country | Link |
---|---|
US (1) | US7393858B2 (de) |
EP (1) | EP1603901B1 (de) |
JP (1) | JP2006519822A (de) |
AT (1) | ATE411311T1 (de) |
AU (1) | AU2004218228A1 (de) |
CA (1) | CA2517422A1 (de) |
DE (1) | DE602004017141D1 (de) |
WO (1) | WO2004078750A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393858B2 (en) | 2003-03-07 | 2008-07-01 | Merck Sharp & Dohme Ltd. | Tetrahydropyran compounds as tachykinin antagonists |
JP5396918B2 (ja) * | 2008-03-14 | 2014-01-22 | Jsr株式会社 | カーボネート基含有化合物及びその(共)重合体の製造方法 |
CA2832864C (en) * | 2011-04-11 | 2018-11-20 | Nippon Filcon Co., Ltd. | Two-layered fabric |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP3310771B1 (de) | 2015-06-19 | 2020-07-22 | Novartis AG | Verbindungen und zusammensetzungen zur inhibition der aktivität von shp2 |
EP3310774B1 (de) | 2015-06-19 | 2020-04-29 | Novartis AG | Verbindungen und zusammensetzungen zur inhibition der aktivität von shp2 |
US11773127B2 (en) * | 2017-11-08 | 2023-10-03 | Washington University | Compounds and methods for treating bacterial infections |
CN112250611B (zh) * | 2020-11-27 | 2022-04-22 | 济南大学 | 一种-2-(2,5-二氟苯基)吡咯烷盐酸盐的合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5150225A1 (es) | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
GB0020721D0 (en) * | 2000-08-22 | 2000-10-11 | Merck Sharp & Dohme | Therapeutic agents |
GB0121874D0 (en) * | 2001-09-10 | 2001-10-31 | Merck Sharp & Dohme | Therapeutic agents |
GB0217068D0 (en) * | 2002-07-23 | 2002-08-28 | Merck Sharp & Dohme | Therapeutic agents |
US7393858B2 (en) | 2003-03-07 | 2008-07-01 | Merck Sharp & Dohme Ltd. | Tetrahydropyran compounds as tachykinin antagonists |
-
2004
- 2004-03-04 US US10/548,678 patent/US7393858B2/en not_active Expired - Fee Related
- 2004-03-04 WO PCT/GB2004/000918 patent/WO2004078750A1/en active Application Filing
- 2004-03-04 EP EP04717163A patent/EP1603901B1/de not_active Expired - Lifetime
- 2004-03-04 JP JP2006505915A patent/JP2006519822A/ja not_active Withdrawn
- 2004-03-04 CA CA002517422A patent/CA2517422A1/en not_active Abandoned
- 2004-03-04 AT AT04717163T patent/ATE411311T1/de not_active IP Right Cessation
- 2004-03-04 DE DE602004017141T patent/DE602004017141D1/de not_active Expired - Fee Related
- 2004-03-04 AU AU2004218228A patent/AU2004218228A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2517422A1 (en) | 2004-09-16 |
US7393858B2 (en) | 2008-07-01 |
US20060172999A1 (en) | 2006-08-03 |
DE602004017141D1 (de) | 2008-11-27 |
EP1603901B1 (de) | 2008-10-15 |
JP2006519822A (ja) | 2006-08-31 |
EP1603901A1 (de) | 2005-12-14 |
AU2004218228A1 (en) | 2004-09-16 |
WO2004078750A1 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
TW200505903A (en) | CGRP receptor antagonists | |
JP2005532372A5 (de) | ||
NO20014529D0 (no) | Tetrahydropyranderivater og deres anvendelse som terapautiske midler | |
WO2006041830A3 (en) | Cgrp receptor antagonists | |
ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
ATE466853T1 (de) | Cgrp-rezeptorantagonisten | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
SE0102055D0 (sv) | New Compounds | |
ATE411311T1 (de) | Tetrahydropyranverbindungen als tachykininantagonisten | |
JO2231B1 (en) | Derivatives of Trahydroperan and its use as a therapeutic agent | |
DK1307192T3 (da) | Candesartan til behandling af migræne | |
BR0212454A (pt) | Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto | |
SE0402763D0 (sv) | Nitro indazole derivatives | |
SE0401343D0 (sv) | Therapeutic compounds: Pyridine N oxide as scaffold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |